HomeFilePharmacology

Pharmacology

Acute Pulmonary Thromboembolism: When Anticoagulation Alone May Not Be Enough

In recent times, pulmonary thromboembolism (PTE) has been the subject of growing research due to its persistent...

TCT 2023 | COMPARE 60/80 HBR TRIAL

This was a randomized study including patients at high risk of bleeding treated with short dual antiplatelet...

TCT 2023 | T-PASS TRIAL, ASA and Ticagrelor in Acute Coronary Syndrome

This is a multicenter randomized study including 2,850 patients with acute coronary syndrome. Patients were randomized to:...

Anti-Lipid Therapy in PCI Patients: Monotherapy with Statins or Combination?

According to several studies, in patients with high-risk atherosclerotic disease, such as those affected by coronary artery...

Substudy TALOS AMI: from Ticagrelor to Clopidogrel in Patients with High Risk of Bleeding and AMI

The preference for the use of potent P2Y12 inhibitors such as ticagrelor and prasugrel in patients with...

ESC 2023 | Anticoagulation After Primary PCI in STEMI Patients

The empirical prescription of anticoagulants after percutaneous coronary intervention (PCI), also know as post-procedural anticoagulation (PPA), is...

ESC 2023 | Extended Monotherapy with Clopidogrel vs. DAPT in High-Risk Patients

An increasing number of patients currently present both an elevated ischemic risk and hemorrhagic risk. This means...

ESC 2023 | STOPDAPT-3 

Short Dual antiplatelet therapy (DAPT), one to three months, followed by P2Y12 inhibitor monotherapy has been shown...